JP7797401B2 - β－ラクタム化合物、プロベネシド、及びバルプロ酸の組み合わせとその使用 - Google Patents

β－ラクタム化合物、プロベネシド、及びバルプロ酸の組み合わせとその使用

Info

Publication number
JP7797401B2
JP7797401B2 JP2022554381A JP2022554381A JP7797401B2 JP 7797401 B2 JP7797401 B2 JP 7797401B2 JP 2022554381 A JP2022554381 A JP 2022554381A JP 2022554381 A JP2022554381 A JP 2022554381A JP 7797401 B2 JP7797401 B2 JP 7797401B2
Authority
JP
Japan
Prior art keywords
day
pharmaceutically acceptable
acceptable salt
probenecid
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022554381A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023517919A5 (https=
JP2023517919A (ja
Inventor
ダン マイケル
Original Assignee
イテルム セラピューティクス インターナショナル リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イテルム セラピューティクス インターナショナル リミティド filed Critical イテルム セラピューティクス インターナショナル リミティド
Publication of JP2023517919A publication Critical patent/JP2023517919A/ja
Publication of JP2023517919A5 publication Critical patent/JP2023517919A5/ja
Application granted granted Critical
Publication of JP7797401B2 publication Critical patent/JP7797401B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2022554381A 2020-03-11 2021-03-11 β－ラクタム化合物、プロベネシド、及びバルプロ酸の組み合わせとその使用 Active JP7797401B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062987963P 2020-03-11 2020-03-11
US62/987,963 2020-03-11
PCT/EP2021/056210 WO2021180857A1 (en) 2020-03-11 2021-03-11 Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof

Publications (3)

Publication Number Publication Date
JP2023517919A JP2023517919A (ja) 2023-04-27
JP2023517919A5 JP2023517919A5 (https=) 2024-03-21
JP7797401B2 true JP7797401B2 (ja) 2026-01-13

Family

ID=74871410

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022554381A Active JP7797401B2 (ja) 2020-03-11 2021-03-11 β－ラクタム化合物、プロベネシド、及びバルプロ酸の組み合わせとその使用

Country Status (10)

Country Link
US (2) US12128034B2 (https=)
EP (1) EP4117645A1 (https=)
JP (1) JP7797401B2 (https=)
KR (1) KR20220152261A (https=)
CN (1) CN115190797B (https=)
AU (1) AU2021235058A1 (https=)
BR (1) BR112022015925A2 (https=)
CA (1) CA3169900A1 (https=)
MX (1) MX2022011238A (https=)
WO (1) WO2021180857A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11554112B2 (en) 2018-06-07 2023-01-17 Herum Therapeutics International Limited Combinations of β-lactam compounds and probenecid and uses thereof
EP3790535A1 (en) 2019-02-13 2021-03-17 Iterum Therapeutics International Limited Combinations of beta-lactam compounds and probenecid and uses thereof
CN116650490B (zh) * 2023-06-07 2025-05-20 中国人民解放军海军军医大学 化合物mt-1207在降低尿酸方面的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019234240A1 (en) 2018-06-07 2019-12-12 Iterum Therapeutics International Limited Combinations of beta-lactam compounds and probenecid and uses thereof
JP7295964B2 (ja) 2019-02-13 2023-06-21 イテルム セラピューティクス インターナショナル リミティド ベータラクタム化合物およびプロベネシドの組み合わせならびにそれらの用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
EP2278999B1 (en) 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
CN101897687B (zh) * 2009-05-26 2012-07-04 中国科学院上海生命科学研究院 丙戊酸钠治疗肝脏炎症相关疾病的新用途
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019234240A1 (en) 2018-06-07 2019-12-12 Iterum Therapeutics International Limited Combinations of beta-lactam compounds and probenecid and uses thereof
JP7295964B2 (ja) 2019-02-13 2023-06-21 イテルム セラピューティクス インターナショナル リミティド ベータラクタム化合物およびプロベネシドの組み合わせならびにそれらの用途

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Ann. Pharmacother.，2005年，39，pp.533-537，DOI 10.1345/aph.1E358
Brain Research，2000年，884，pp.77-86
Clin. Pharmacokinet.，2019年，58，pp.875-886
Drug Metabolism and Disposition，2000年，28(12)，pp.1433-1439
Ther. Drug Monit.，2012年，34(5)，pp.599-603
U.S. Securities and Exchange Commission, Iterum Therapeutics plc，Registration No. 333，2018年，page.1-3,97-99，https://ir.iterumtx.com/sec-filings/content/0001193125-18-146797/0001193125-18-146797.pdf

Also Published As

Publication number Publication date
EP4117645A1 (en) 2023-01-18
US12128034B2 (en) 2024-10-29
US20250120953A1 (en) 2025-04-17
CN115190797B (zh) 2025-07-11
AU2021235058A1 (en) 2022-09-01
CN115190797A (zh) 2022-10-14
MX2022011238A (es) 2022-10-07
JP2023517919A (ja) 2023-04-27
KR20220152261A (ko) 2022-11-15
WO2021180857A1 (en) 2021-09-16
BR112022015925A2 (pt) 2022-10-04
CA3169900A1 (en) 2021-09-16
US20210283112A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
US12109197B2 (en) Combinations of β-lactam compounds and probenecid and uses thereof
US20250120953A1 (en) Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof
AU2019429755B2 (en) Combinations of beta-lactam compounds and probenecid and uses thereof
JP7651203B2 (ja) ボロン酸誘導体およびその治療的使用
CA3129337C (en) Combinations of beta-lactam compounds and probenecid and uses thereof
HK40051087A (en) Combinations of beta-lactam compounds and probenecid and uses thereof
HK40112831A (zh) β-内酰胺化合物与丙磺舒的组合及其用途
HK40119347A (zh) β-内酰胺化合物和丙磺舒的组合及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240311

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240311

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250911

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251224

R150 Certificate of patent or registration of utility model

Ref document number: 7797401

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150